As SOAT1 is the target of mitotane, a drug used for the treatment of adrenocortical carcinoma, it would be interesting to investigate whether SOAT1 inhibition could also interfere with cholesterol metabolism in PCa cells49. Here, SOAT1 is linked to adrenal cortex carcinoma.